{"transactions":[{"id":739582,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T14:40:06.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in 12 substantially equal monthly installments commencing on July 11, 2026, subject to the Reporting Person's Continuous Service (as defined in the company's 2021 Equity Incentive Plan, the \"Plan\") through the vesting dates. Any portion of the option not vested on the date of the next annual stockholder meeting will vest in full, subject to the Reporting Person's Continuous Service through such date. The option will also vest in full in the event of the Reporting Person's death, Disability (as defined in the Plan) or upon a Change in Control (as defined in the Plan)."}],"balance_after":6500,"derivative":{"exercise_price":7.93,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001402856-26-000003","document":"wk-form4_1781289604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000140285626000003/wk-form4_1781289604.xml","form_type":"4"}},{"id":1130427,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-29T19:09:15.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in 12 substantially equal monthly installments commencing on June 28, 2025, subject to the Reporting Person's Continuous Service (as defined in the company's 2021 Equity Incentive Plan, the \"Plan\") through the vesting dates. Any portion of the option not vested on the date of the next annual stockholder meeting will vest in full, subject to the Reporting Person's Continuous Service through such date. The option will also vest in full in the event of the Reporting Person's death, Disability (as defined in the Plan) or upon a Change in Control (as defined in the Plan)."}],"balance_after":6500,"derivative":{"exercise_price":26.75,"expiration_date":"2035-05-27","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001789769-25-000064","document":"wk-form4_1748560149.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000178976925000064/wk-form4_1748560149.xml","form_type":"4"}},{"id":1480445,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-13T17:02:15.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in 12 substantially equal monthly installments commencing on July 13, 2024, subject to the Reporting Person's Continuous Service (as defined in the company's 2021 Equity Incentive Plan, the \"Plan\") through the vesting dates. Any portion of the option not vested on the date of the next annual stockholder meeting will vest in full, subject to the Reporting Person's Continuous Service through such date. The option will also vest in full in the event of the Reporting Person's death, Disability (as defined in the Plan) or upon a Change in Control (as defined in the Plan)."}],"balance_after":5000,"derivative":{"exercise_price":10.5,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001789769-24-000065","document":"wk-form4_1718312526.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000178976924000065/wk-form4_1718312526.xml","form_type":"4"}},{"id":1524585,"issuer":{"id":4831,"kind":"organization","name":"PROCEPT BioRobotics Corp","symbol":"PRCT"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"ten_percent_owner":true}},{"id":91372,"kind":"organization","name":"CPMG Inc","position":2,"cik":"0001372218","reported_name":"CPMG Inc","relationship":{"ten_percent_owner":true}},{"id":91373,"kind":"organization","name":"White Tailed Ptarmigan, LP","position":3,"cik":"0001882743","reported_name":"White Tailed Ptarmigan, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-05-07T21:46:20.000Z","date":"2024-05-03","kind":"other","planned":false,"acquired":false,"shares":1785127,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By White Tailed Ptarmigan, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 3, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 421,061 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On May 3, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 421,061 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the \"CPMG Funds\"). In such capacities, CPMG, Inc. may be deemed to have voting and investment control over the shares beneficially owned by the CPMG Funds. Antal Desai, a member of the Issuer's board of directors, and Kent McGaughy, Jr., each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Antal Desai reports his beneficial ownership of these shares on a separate Form 4."}],"balance_after":2823681,"source":{"system":"sec-edgar","filing":"0000905148-24-001300","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514824001300/form4.xml","form_type":"4"}},{"id":1681484,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-10T19:50:54.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in 12 equal monthly installments commencing on July 14, 2023, subject to the Report Person's continued service as a director through the vesting date."}],"balance_after":1500,"derivative":{"exercise_price":11.18,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001789769-24-000010","document":"wk-form4_1704934245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000178976924000010/wk-form4_1704934245.xml","form_type":"4"}},{"id":1773269,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":892,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":88.75,"expiration_date":"2029-06-12","underlying":"Class B common stock","underlying_shares":892},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773268,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":88.75,"expiration_date":"2029-06-12","underlying":"Class B common stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773267,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1844,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":39.48,"expiration_date":"2028-06-13","underlying":"Class B common stock","underlying_shares":1844},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773266,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":39.48,"expiration_date":"2028-06-13","underlying":"Class B common stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773265,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3185,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":25.52,"expiration_date":"2027-06-14","underlying":"Class B common stock","underlying_shares":3185},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773264,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":25.52,"expiration_date":"2027-06-14","underlying":"Class B common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773263,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2773,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":22.57,"expiration_date":"2026-12-07","underlying":"Class B common stock","underlying_shares":2773},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773262,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)/","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":22.57,"expiration_date":"2026-12-07","underlying":"Class B common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773261,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4275,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":93.61,"expiration_date":"2033-06-07","underlying":"Class A common stock","underlying_shares":4275},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773260,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1628,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":93.61,"expiration_date":"2033-06-07","underlying":"Class A common stock","underlying_shares":1628},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773259,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4787,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":34.76,"expiration_date":"2032-06-08","underlying":"Class A common stock","underlying_shares":4787},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773258,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11240,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":34.76,"expiration_date":"2032-06-08","underlying":"Class A common stock","underlying_shares":11240},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773257,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":399,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":27.32,"expiration_date":"2032-01-03","underlying":"Class A common stock","underlying_shares":399},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773256,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":690,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":146.01,"expiration_date":"2031-06-10","underlying":"Class A common stock","underlying_shares":690},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773255,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":146.01,"expiration_date":"2031-06-10","underlying":"Class A common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773254,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":699,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":130.92,"expiration_date":"2030-06-10","underlying":"Class A common stock","underlying_shares":699},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773253,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":130.92,"expiration_date":"2030-06-10","underlying":"Class A common stock","underlying_shares":6300},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773252,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class B common stock","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":278309,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A common stock","underlying_shares":278309},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773251,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class B common stock","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3109,"ownership":{"direct":false,"nature":"By Traweek Children's Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is trustee of Traweek Children's Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Class A common stock","underlying_shares":3109},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773250,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class B common stock","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":51095,"ownership":{"direct":false,"nature":"By Lagos Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is trustee of Lagos Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Class A common stock","underlying_shares":51095},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773249,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class B common stock","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1692857,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Class B common stock was convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of Class A common stock were held in various funds for which CPMG, Inc. serves as investment manager. Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Class A common stock","underlying_shares":1692857},"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773248,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":280,"ownership":{"direct":false,"nature":"By Traweek Children's Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is trustee of Traweek Children's Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773247,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4591,"ownership":{"direct":false,"nature":"By Lagos Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is trustee of Lagos Trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773246,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2896901,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of Class A common stock were held in various funds for which CPMG, Inc. serves as investment manager. Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1773245,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2023-09-26T19:18:56.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25004,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes,... (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) ...and (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000905148-23-001010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514823001010/form4.xml","form_type":"4"}},{"id":1860370,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T16:30:38.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":4275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 4 equal installments on September 7, 2023, December 7, 2023, March 7, 2024, and June 5, 2024, subject to continued service through each vesting date."}],"balance_after":4275,"derivative":{"exercise_price":93.61,"expiration_date":"2033-06-07","underlying":"Class A common stock","underlying_shares":4275},"source":{"system":"sec-edgar","filing":"0001140361-23-029139","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036123029139/form4.xml","form_type":"4"}},{"id":1860369,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T16:30:38.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":1628,"price":73.68,"value":119951.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $119,954."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 4 equal installments on September 7, 2023, December 7, 2023, March 7, 2024, and June 5, 2024, subject to continued service through each vesting date."}],"balance_after":1628,"derivative":{"exercise_price":93.61,"expiration_date":"2033-06-07","underlying":"Class A common stock","underlying_shares":1628},"source":{"system":"sec-edgar","filing":"0001140361-23-029139","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036123029139/form4.xml","form_type":"4"}},{"id":1927623,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-04T20:15:52.000Z","date":"2023-04-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":38667,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the \"inducement\" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the \"Issuer Stock Plans\", and each such option, an \"Issuer Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the \"inducement\" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the \"Issuer Stock Plans\", and each such option, an \"Issuer Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the \"inducement\" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the \"Issuer Stock Plans\", and each such option, an \"Issuer Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions."}],"balance_after":0,"derivative":{"exercise_price":3.95,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":38667},"source":{"system":"sec-edgar","filing":"0001140361-23-016441","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036123016441/form4.xml","form_type":"4"}},{"id":1927622,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-04-04T20:15:52.000Z","date":"2023-04-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400675,"ownership":{"direct":false,"nature":"By Mallard Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects the disposition of the Reporting Person's indirectly owned shares of the Issuer's common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the disposition of the Reporting Person's indirectly owned shares of the Issuer's common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-016441","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036123016441/form4.xml","form_type":"4"}},{"id":1927621,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-04-04T20:15:52.000Z","date":"2023-04-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":63671,"ownership":{"direct":false,"nature":"By Kestrel Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects the disposition of the Reporting Person's indirectly owned shares of the Issuer's common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the disposition of the Reporting Person's indirectly owned shares of the Issuer's common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-016441","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036123016441/form4.xml","form_type":"4"}},{"id":1927620,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-04-04T20:15:52.000Z","date":"2023-04-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45594,"ownership":{"direct":false,"nature":"By Crested Crane, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects the disposition of the Reporting Person's indirectly owned shares of the Issuer's common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the disposition of the Reporting Person's indirectly owned shares of the Issuer's common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-016441","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036123016441/form4.xml","form_type":"4"}},{"id":1927619,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-04-04T20:15:52.000Z","date":"2023-04-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3687781,"ownership":{"direct":false,"nature":"By Roadrunner Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects the disposition of the Reporting Person's indirectly owned shares of the Issuer's common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the disposition of the Reporting Person's indirectly owned shares of the Issuer's common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-016441","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036123016441/form4.xml","form_type":"4"}},{"id":1927618,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-04-04T20:15:52.000Z","date":"2023-04-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1310701,"ownership":{"direct":false,"nature":"By Killdeer Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects the disposition of the Reporting Person's indirectly owned shares of the Issuer's common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the disposition of the Reporting Person's indirectly owned shares of the Issuer's common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-016441","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036123016441/form4.xml","form_type":"4"}},{"id":1927617,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-04-04T20:15:52.000Z","date":"2023-04-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":675181,"ownership":{"direct":false,"nature":"By Curlew Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects the disposition of the Reporting Person's indirectly owned shares of the Issuer's common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the disposition of the Reporting Person's indirectly owned shares of the Issuer's common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-016441","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036123016441/form4.xml","form_type":"4"}},{"id":1965578,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2023-03-07T16:37:08.000Z","date":"2023-03-03","kind":"gift","acquired":false,"shares":33217,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of Class A common stock are held in escrow for a charitable donee by American Stock Transfer & Trust Company, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-010508","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036123010508/form4.xml","form_type":"4"}},{"id":2074148,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"6.0% Convertible Debentures due 2026","published_at":"2022-12-30T17:25:51.000Z","date":"2022-12-28","kind":"exercise","acquired":false,"price":0,"reported_value":4763750,"ownership":{"direct":false,"nature":"By Roadrunner Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 28, 2022 (the \"Forced Conversion Date\"), the Issuer notified the holders of its outstanding 6.0% Convertible Debentures due 2026 (the \"Debentures\") that it elected to cause the eligible portion of the aggregate principal amount of the Debentures outstanding to be converted into shares of the Issuer's common stock at the fixed conversion price of $3.25 per share and to issue shares of the Issuer's common stock to satisfy accrued but unpaid interest on the principal amount to be converted through the Forced Conversion Date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.25,"exercise_date":"2019-08-12","expiration_date":"2026-08-12","underlying":"Common Stock","underlying_shares":1465770},"source":{"system":"sec-edgar","filing":"0001140361-22-047719","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036122047719/form4.xml","form_type":"4"}},{"id":2074147,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"6.0% Convertible Debentures due 2026","published_at":"2022-12-30T17:25:51.000Z","date":"2022-12-28","kind":"exercise","acquired":false,"price":0,"reported_value":1905500,"ownership":{"direct":false,"nature":"By Killdeer Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 28, 2022 (the \"Forced Conversion Date\"), the Issuer notified the holders of its outstanding 6.0% Convertible Debentures due 2026 (the \"Debentures\") that it elected to cause the eligible portion of the aggregate principal amount of the Debentures outstanding to be converted into shares of the Issuer's common stock at the fixed conversion price of $3.25 per share and to issue shares of the Issuer's common stock to satisfy accrued but unpaid interest on the principal amount to be converted through the Forced Conversion Date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.25,"exercise_date":"2019-08-12","expiration_date":"2026-08-12","underlying":"Common Stock","underlying_shares":586308},"source":{"system":"sec-edgar","filing":"0001140361-22-047719","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036122047719/form4.xml","form_type":"4"}},{"id":2074146,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"6.0% Convertible Debentures due 2026","published_at":"2022-12-30T17:25:51.000Z","date":"2022-12-28","kind":"exercise","acquired":false,"price":0,"reported_value":476375,"ownership":{"direct":false,"nature":"By Curlew Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 28, 2022 (the \"Forced Conversion Date\"), the Issuer notified the holders of its outstanding 6.0% Convertible Debentures due 2026 (the \"Debentures\") that it elected to cause the eligible portion of the aggregate principal amount of the Debentures outstanding to be converted into shares of the Issuer's common stock at the fixed conversion price of $3.25 per share and to issue shares of the Issuer's common stock to satisfy accrued but unpaid interest on the principal amount to be converted through the Forced Conversion Date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.25,"exercise_date":"2019-08-12","expiration_date":"2026-08-12","underlying":"Common Stock","underlying_shares":146577},"source":{"system":"sec-edgar","filing":"0001140361-22-047719","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036122047719/form4.xml","form_type":"4"}},{"id":2074145,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2022-12-30T17:25:51.000Z","date":"2022-12-28","kind":"exercise","acquired":true,"shares":1465770,"price":3.25,"value":4763752.5,"ownership":{"direct":false,"nature":"By Roadrunner Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 28, 2022 (the \"Forced Conversion Date\"), the Issuer notified the holders of its outstanding 6.0% Convertible Debentures due 2026 (the \"Debentures\") that it elected to cause the eligible portion of the aggregate principal amount of the Debentures outstanding to be converted into shares of the Issuer's common stock at the fixed conversion price of $3.25 per share and to issue shares of the Issuer's common stock to satisfy accrued but unpaid interest on the principal amount to be converted through the Forced Conversion Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"This amount includes an aggregate 70,802 shares issued by the Issuer to the Roadrunner Fund, LP since the last Form 4 filed by the Reporting Person on October 19, 2021, including 56,598 shares paid in the semi-annual interest payments in January 2022 and in July 2022, and 14,204 shares paid on accrued but unpaid interest through the Forced Conversion Date, on the Debentures held by the Roadrunner Fund, LP, which transactions were exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9(a)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":3687781,"source":{"system":"sec-edgar","filing":"0001140361-22-047719","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036122047719/form4.xml","form_type":"4"}},{"id":2074144,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2022-12-30T17:25:51.000Z","date":"2022-12-28","kind":"exercise","acquired":true,"shares":586308,"price":3.25,"value":1905501.0,"ownership":{"direct":false,"nature":"By Killdeer Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 28, 2022 (the \"Forced Conversion Date\"), the Issuer notified the holders of its outstanding 6.0% Convertible Debentures due 2026 (the \"Debentures\") that it elected to cause the eligible portion of the aggregate principal amount of the Debentures outstanding to be converted into shares of the Issuer's common stock at the fixed conversion price of $3.25 per share and to issue shares of the Issuer's common stock to satisfy accrued but unpaid interest on the principal amount to be converted through the Forced Conversion Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"This amount includes an aggregate 28,322 shares issued by the Issuer to the Killdeer Fund, LP since the last Form 4 filed by the Reporting Person on October 19, 2021, including 22,640 shares paid in the semi-annual interest payments in January 2022 and in July 2022, and 5,682 shares paid on accrued but unpaid interest through the Forced Conversion Date, on the Debentures held by the Killdeer Fund, LP, which transactions were exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9(a)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":1310701,"source":{"system":"sec-edgar","filing":"0001140361-22-047719","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036122047719/form4.xml","form_type":"4"}},{"id":2074143,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2022-12-30T17:25:51.000Z","date":"2022-12-28","kind":"exercise","acquired":true,"shares":146577,"price":3.25,"value":476375.25,"ownership":{"direct":false,"nature":"By Curlew Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 28, 2022 (the \"Forced Conversion Date\"), the Issuer notified the holders of its outstanding 6.0% Convertible Debentures due 2026 (the \"Debentures\") that it elected to cause the eligible portion of the aggregate principal amount of the Debentures outstanding to be converted into shares of the Issuer's common stock at the fixed conversion price of $3.25 per share and to issue shares of the Issuer's common stock to satisfy accrued but unpaid interest on the principal amount to be converted through the Forced Conversion Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This amount includes an aggregate 7,082 shares issued by the Issuer to the Curlew Fund, LP since the last Form 4 filed by the Reporting Person on October 19, 2021, including 5,661 shares paid in the semi-annual interest payments in January 2022 and in July 2022, and 1,421 shares paid on accrued but unpaid interest through the Forced Conversion Date, on the Debentures held by the Curlew Fund, LP, which transactions were exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9(a)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). Each of the Reporting Person and Antal Desai is a shareholder and managing partner of CPMG, Inc.  In such capacities, each of CPMG, Inc., the Reporting Person and Antal Desai may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Each of CPMG, Inc. and Antal Desai reports its and his beneficial ownership of these shares on a separate Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":675181,"source":{"system":"sec-edgar","filing":"0001140361-22-047719","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036122047719/form4.xml","form_type":"4"}},{"id":2093192,"issuer":{"id":4831,"kind":"organization","name":"PROCEPT BioRobotics Corp","symbol":"PRCT"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"ten_percent_owner":true}},{"id":91372,"kind":"organization","name":"CPMG Inc","position":2,"cik":"0001372218","reported_name":"CPMG Inc","relationship":{"ten_percent_owner":true}},{"id":91373,"kind":"organization","name":"White Tailed Ptarmigan, LP","position":3,"cik":"0001882743","reported_name":"White Tailed Ptarmigan, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2022-12-07T16:32:31.000Z","date":"2022-12-05","kind":"other","acquired":false,"shares":1726534,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By White Tailed Ptarmigan, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 5, 2022, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 236,734 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 5, 2022, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 236,734 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P., and Mallard Fund, L.P. (collectively, the \"CPMG Funds\"). In such capacities, CPMG, Inc. may be deemed to have voting and investment control over the shares beneficially owned by the CPMG Funds. Antal Desai, a member of the Issuer's board of directors, and Kent McGaughy, Jr., each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Antal Desai reports his beneficial ownership of these shares on a separate Form 4."}],"balance_after":5029869,"source":{"system":"sec-edgar","filing":"0001140361-22-044739","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036122044739/form4.xml","form_type":"4"}},{"id":2114398,"issuer":{"id":4831,"kind":"organization","name":"PROCEPT BioRobotics Corp","symbol":"PRCT"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"ten_percent_owner":true}},{"id":91372,"kind":"organization","name":"CPMG Inc","position":2,"cik":"0001372218","reported_name":"CPMG Inc","relationship":{"ten_percent_owner":true}},{"id":91373,"kind":"organization","name":"White Tailed Ptarmigan, LP","position":3,"cik":"0001882743","reported_name":"White Tailed Ptarmigan, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2022-11-16T16:31:04.000Z","date":"2022-11-14","kind":"other","acquired":false,"shares":1729482,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By White Tailed Ptarmigan, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On November 14, 2022, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 233,056 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 14, 2022, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 233,056 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P., and Mallard Fund, L.P. (collectively, the \"CPMG Funds\"). In such capacities,\nCPMG, Inc. may be deemed to have voting and investment control over the shares beneficially owned by the CPMG Funds. Antal Desai, a member of the Issuer's board of directors, and Kent McGaughy, Jr., each of whom is a shareholder and\nmanaging partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares\nbeneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Antal Desai reports his beneficial ownership of these shares on a separate Form 4."}],"balance_after":6993137,"source":{"system":"sec-edgar","filing":"0001140361-22-041922","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036122041922/form4.xml","form_type":"4"}},{"id":2160090,"issuer":{"id":4831,"kind":"organization","name":"PROCEPT BioRobotics Corp","symbol":"PRCT"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"ten_percent_owner":true}},{"id":91372,"kind":"organization","name":"CPMG Inc","position":2,"cik":"0001372218","reported_name":"CPMG Inc","relationship":{"ten_percent_owner":true}},{"id":91373,"kind":"organization","name":"White Tailed Ptarmigan, LP","position":3,"cik":"0001882743","reported_name":"White Tailed Ptarmigan, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2022-09-13T16:45:48.000Z","date":"2022-09-09","kind":"other","acquired":false,"shares":986640,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By White Tailed Ptarmigan, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 9, 2022, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 133,176 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 9, 2022, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 133,176 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the general partner of White Tailed Ptarmigan, LP and the investment manager of each of Kestrel Fund, L.P. and Mallard Fund, L.P. (together with White Tailed Ptarmigan, LP, the \"CPMG Funds\").  In such capacities, CPMG, Inc. may be deemed to have voting and investment control over the shares beneficially owned by the CPMG Funds. Antal Desai, a member of the Issuer's board of directors, and Kent McGaughy, Jr., each of whom is a shareholder and managing director of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds.  Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Antal Desai reports his beneficial ownership of these shares on a separate Form 4."}],"balance_after":8955675,"source":{"system":"sec-edgar","filing":"0001140361-22-033193","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036122033193/form4.xml","form_type":"4"}},{"id":2163164,"issuer":{"id":4831,"kind":"organization","name":"PROCEPT BioRobotics Corp","symbol":"PRCT"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"ten_percent_owner":true}},{"id":91372,"kind":"organization","name":"CPMG Inc","position":2,"cik":"0001372218","reported_name":"CPMG Inc","relationship":{"ten_percent_owner":true}},{"id":91373,"kind":"organization","name":"White Tailed Ptarmigan, LP","position":3,"cik":"0001882743","reported_name":"White Tailed Ptarmigan, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2022-09-08T16:46:04.000Z","date":"2022-09-06","kind":"other","acquired":false,"shares":743021,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By White Tailed Ptarmigan, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 6, 2022, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 99,881 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 6, 2022, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 99,881 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the general partner of White Tailed Ptarmigan, LP and the investment manager of each of Kestrel Fund, L.P. and Mallard Fund, L.P. (together with White Tailed Ptarmigan, LP, the \"CPMG Funds\"). In such capacities, CPMG, Inc. may be deemed to have voting and investment control over the shares beneficially owned by the CPMG Funds. Antal Desai, a member of the Issuer's board of directors, and Kent McGaughy, Jr., each of whom is a shareholder and managing director of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. Antal Desai reports his beneficial ownership of these shares on a separate Form 4."}],"balance_after":10075491,"source":{"system":"sec-edgar","filing":"0001140361-22-032770","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036122032770/form4.xml","form_type":"4"}},{"id":2229840,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T21:16:46.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":38667,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":38667,"derivative":{"exercise_price":3.95,"exercise_date":"2023-06-14","expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":38667},"source":{"system":"sec-edgar","filing":"0001251769-22-000051","document":"wf-form4_165542857767463.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000125176922000051/wf-form4_165542857767463.xml","form_type":"4"}},{"id":2235739,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T18:33:24.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":4787,"price":24.02,"value":114983.74,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These options were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $115,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 4 equal installments on September 14, 2022, December 8, 2022, March 1, 2023, and June 7, 2023, subject to continued service through each vesting date."}],"balance_after":4787,"derivative":{"exercise_price":34.76,"expiration_date":"2032-06-08","underlying":"Class A common stock","underlying_shares":4787},"source":{"system":"sec-edgar","filing":"0001567619-22-012701","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000156761922012701/doc1.xml","form_type":"4"}},{"id":2235738,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T18:33:24.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":11240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 4 equal installments on September 14, 2022, December 8, 2022, March 1, 2023, and June 7, 2023, subject to continued service through each vesting date."}],"balance_after":11240,"derivative":{"exercise_price":34.76,"expiration_date":"2032-06-08","underlying":"Class A common stock","underlying_shares":11240},"source":{"system":"sec-edgar","filing":"0001567619-22-012701","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000156761922012701/doc1.xml","form_type":"4"}},{"id":2256569,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-05-25T17:59:15.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in 12 equal monthly installments commencing on June 20, 2022, subject to the Report Person's continued service as a director through the vesting date."}],"balance_after":30000,"derivative":{"exercise_price":7.27,"expiration_date":"2032-05-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001789769-22-000047","document":"wf-form4_165351593893691.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000178976922000047/wf-form4_165351593893691.xml","form_type":"4"}},{"id":2322994,"issuer":{"id":4831,"kind":"organization","name":"PROCEPT BioRobotics Corp","symbol":"PRCT"},"owners":[{"id":91372,"kind":"organization","name":"CPMG Inc","position":1,"cik":"0001372218","reported_name":"CPMG Inc","relationship":{"ten_percent_owner":true}},{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":2,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"ten_percent_owner":true}},{"id":91373,"kind":"organization","name":"White Tailed Ptarmigan, LP","position":3,"cik":"0001882743","reported_name":"White Tailed Ptarmigan, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2022-03-21T18:22:17.000Z","date":"2022-03-17","kind":"other","acquired":false,"shares":304268,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By White Tailed Ptarmigan, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"White Tailed Ptarmigan, LP distributed these shares to one of its partners on a pro rata basis, for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the general partner of White Tailed Ptarmigan, LP and has voting and investment control over the shares beneficially owned by White Tailed Ptarmigan, LP. Antal Desai, a member of our board of directors and a Partner of CPMG, Inc., along with Kent McGaughy, Jr., the sole shareholder and managing director of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by White Tailed Ptarmigan, LP. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by White Tailed Ptarmigan, LP except to the extent of any pecuniary interest therein. Antal Desai is separately reporting his deemed indirect ownership of the shares held by White Tailed Ptarmigan, LP."}],"balance_after":10918394,"source":{"system":"sec-edgar","filing":"0001140361-22-010390","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036122010390/form4.xml","form_type":"4"}},{"id":2327132,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-17T16:56:19.000Z","date":"2022-03-15","kind":"other","acquired":false,"shares":260323,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The LP distributed these shares to its partners on a pro rata basis, for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Ibisbill, LP (the \"LP\"). CPMG, Inc. is the general partner of the LP and has voting and investment control over the shares beneficially owned by the LP. The Reporting Person is the sole shareholder and managing director of CPMG, Inc. and may be deemed to share voting and investment power with respect to the shares beneficially owned by the LP. The Reporting Person disclaims beneficial ownership of the shares beneficially owned by LP except to the extent of any pecuniary interest therein."}],"balance_after":8218467,"source":{"system":"sec-edgar","filing":"0001567619-22-007150","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000156761922007150/doc1.xml","form_type":"4"}},{"id":2443476,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T17:22:16.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":399,"price":16.14,"value":6439.86,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $6,456."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 2 equal installments on March 10, 2022 and June 10, 2022, subject to continued service through each vesting date."}],"balance_after":399,"derivative":{"exercise_price":27.32,"expiration_date":"2032-01-03","underlying":"Class A common stock","underlying_shares":399},"source":{"system":"sec-edgar","filing":"0000905148-22-000004","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514822000004/form4.xml","form_type":"4"}},{"id":2539094,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2021-10-19T18:41:40.000Z","date":"2021-10-15","kind":"purchase","acquired":true,"shares":387097,"price":7.75,"value":3000001.75,"ownership":{"direct":false,"nature":"By Roadrunner Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were acquired in an underwritten registered follow-on offering by the Issuer that closed on October 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were acquired in an underwritten registered follow-on offering by the Issuer that closed on October 15, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"This amount includes an aggregate 56,904 shares issued by the Issuer to the Roadrunner Fund, LP since the last Form 4 filed by the Reporting Person on July 21, 2020, as the semi-annual interest payments, in January 2021 and in July 2021, on the 6.0% Convertible Debentures due 2024 held by the Roadrunner Fund, LP, which transactions were exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9(a)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). The Reporting Person is the Managing Director of CPMG, Inc.  In such capacity, the Reporting Person may be deemed to exercise voting and investment control over the securities owned by each of the Funds.  The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). The Reporting Person is the Managing Director of CPMG, Inc.  In such capacity, the Reporting Person may be deemed to exercise voting and investment control over the securities owned by each of the Funds.  The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":2151209,"source":{"system":"sec-edgar","filing":"0001140361-21-034925","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036121034925/form4.xml","form_type":"4"}},{"id":2539093,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2021-10-19T18:41:40.000Z","date":"2021-10-15","kind":"purchase","acquired":true,"shares":258064,"price":7.75,"value":1999996.0,"ownership":{"direct":false,"nature":"By Killdeer Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were acquired in an underwritten registered follow-on offering by the Issuer that closed on October 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were acquired in an underwritten registered follow-on offering by the Issuer that closed on October 15, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This amount includes an aggregate 22,763 shares issued by the Issuer to the Killdeer Fund, LP since the last Form 4 filed by the Reporting Person on July 21, 2020, as the semi-annual interest payments, in January 2021 and in July 2021, on the 6.0% Convertible Debentures due 2024 held by the Killdeer Fund, LP, which transactions were exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9(a)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). The Reporting Person is the Managing Director of CPMG, Inc.  In such capacity, the Reporting Person may be deemed to exercise voting and investment control over the securities owned by each of the Funds.  The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). The Reporting Person is the Managing Director of CPMG, Inc.  In such capacity, the Reporting Person may be deemed to exercise voting and investment control over the securities owned by each of the Funds.  The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":696071,"source":{"system":"sec-edgar","filing":"0001140361-21-034925","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036121034925/form4.xml","form_type":"4"}},{"id":2539092,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2021-10-19T18:41:40.000Z","date":"2021-10-15","kind":"purchase","acquired":true,"shares":38710,"price":7.75,"value":300002.5,"ownership":{"direct":false,"nature":"By Curlew Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were acquired in an underwritten registered follow-on offering by the Issuer that closed on October 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were acquired in an underwritten registered follow-on offering by the Issuer that closed on October 15, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This amount includes an aggregate 5,692 shares issued by the Issuer to the Curlew Fund, LP since the last Form 4 filed by the Reporting Person on July 21, 2020, as the semi-annual interest payments, in January 2021 and in July 2021, on the 6.0% Convertible Debentures due 2024 held by the Curlew Fund, LP, which transactions were exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9(a)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). The Reporting Person is the Managing Director of CPMG, Inc.  In such capacity, the Reporting Person may be deemed to exercise voting and investment control over the securities owned by each of the Funds.  The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the \"Funds\"). The Reporting Person is the Managing Director of CPMG, Inc.  In such capacity, the Reporting Person may be deemed to exercise voting and investment control over the securities owned by each of the Funds.  The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":521522,"source":{"system":"sec-edgar","filing":"0001140361-21-034925","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036121034925/form4.xml","form_type":"4"}},{"id":2562998,"issuer":{"id":4831,"kind":"organization","name":"PROCEPT BioRobotics Corp","symbol":"PRCT"},"owners":[{"id":91372,"kind":"organization","name":"CPMG Inc","position":1,"cik":"0001372218","reported_name":"CPMG Inc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":2,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":91373,"kind":"organization","name":"White Tailed Ptarmigan, LP","position":3,"cik":"0001882743","reported_name":"White Tailed Ptarmigan, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Convertible Preferred Stock","published_at":"2021-09-21T18:34:24.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":272205,"ownership":{"direct":false,"nature":"By White Tailed Ptarmigan, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"CPMG, Inc. is the general partner of White Tailed Ptarmigan, LP and has voting and investment control over the shares beneficially owned by White Tailed Ptarmigan, LP. Antal Desai, a member of our board of directors and a Partner of CPMG, Inc., along with Kent McGaughy, Jr., the sole shareholder and managing director of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by White Tailed Ptarmigan, LP. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by White Tailed Ptarmigan, LP except to the extent of any pecuniary interest therein. Antal Desai is separately reporting his deemed indirect ownership of the shares held by White Tailed Ptarmigan, LP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":272205},"source":{"system":"sec-edgar","filing":"0001628280-21-018953","document":"wf-form4_163226365231972.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000162828021018953/wf-form4_163226365231972.xml","form_type":"4"}},{"id":2562997,"issuer":{"id":4831,"kind":"organization","name":"PROCEPT BioRobotics Corp","symbol":"PRCT"},"owners":[{"id":91372,"kind":"organization","name":"CPMG Inc","position":1,"cik":"0001372218","reported_name":"CPMG Inc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":2,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":91373,"kind":"organization","name":"White Tailed Ptarmigan, LP","position":3,"cik":"0001882743","reported_name":"White Tailed Ptarmigan, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Convertible Preferred Stock","published_at":"2021-09-21T18:34:24.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":2060802,"ownership":{"direct":false,"nature":"By White Tailed Ptarmigan, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"CPMG, Inc. is the general partner of White Tailed Ptarmigan, LP and has voting and investment control over the shares beneficially owned by White Tailed Ptarmigan, LP. Antal Desai, a member of our board of directors and a Partner of CPMG, Inc., along with Kent McGaughy, Jr., the sole shareholder and managing director of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by White Tailed Ptarmigan, LP. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by White Tailed Ptarmigan, LP except to the extent of any pecuniary interest therein. Antal Desai is separately reporting his deemed indirect ownership of the shares held by White Tailed Ptarmigan, LP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2060802},"source":{"system":"sec-edgar","filing":"0001628280-21-018953","document":"wf-form4_163226365231972.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000162828021018953/wf-form4_163226365231972.xml","form_type":"4"}},{"id":2562996,"issuer":{"id":4831,"kind":"organization","name":"PROCEPT BioRobotics Corp","symbol":"PRCT"},"owners":[{"id":91372,"kind":"organization","name":"CPMG Inc","position":1,"cik":"0001372218","reported_name":"CPMG Inc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":2,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":91373,"kind":"organization","name":"White Tailed Ptarmigan, LP","position":3,"cik":"0001882743","reported_name":"White Tailed Ptarmigan, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Convertible Preferred Stock","published_at":"2021-09-21T18:34:24.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":3038934,"ownership":{"direct":false,"nature":"By White Tailed Ptarmigan, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"CPMG, Inc. is the general partner of White Tailed Ptarmigan, LP and has voting and investment control over the shares beneficially owned by White Tailed Ptarmigan, LP. Antal Desai, a member of our board of directors and a Partner of CPMG, Inc., along with Kent McGaughy, Jr., the sole shareholder and managing director of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by White Tailed Ptarmigan, LP. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by White Tailed Ptarmigan, LP except to the extent of any pecuniary interest therein. Antal Desai is separately reporting his deemed indirect ownership of the shares held by White Tailed Ptarmigan, LP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3038934},"source":{"system":"sec-edgar","filing":"0001628280-21-018953","document":"wf-form4_163226365231972.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000162828021018953/wf-form4_163226365231972.xml","form_type":"4"}},{"id":2562995,"issuer":{"id":4831,"kind":"organization","name":"PROCEPT BioRobotics Corp","symbol":"PRCT"},"owners":[{"id":91372,"kind":"organization","name":"CPMG Inc","position":1,"cik":"0001372218","reported_name":"CPMG Inc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":2,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":91373,"kind":"organization","name":"White Tailed Ptarmigan, LP","position":3,"cik":"0001882743","reported_name":"White Tailed Ptarmigan, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2021-09-21T18:34:24.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":4712969,"ownership":{"direct":false,"nature":"By White Tailed Ptarmigan, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"CPMG, Inc. is the general partner of White Tailed Ptarmigan, LP and has voting and investment control over the shares beneficially owned by White Tailed Ptarmigan, LP. Antal Desai, a member of our board of directors and a Partner of CPMG, Inc., along with Kent McGaughy, Jr., the sole shareholder and managing director of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by White Tailed Ptarmigan, LP. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by White Tailed Ptarmigan, LP except to the extent of any pecuniary interest therein. Antal Desai is separately reporting his deemed indirect ownership of the shares held by White Tailed Ptarmigan, LP."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4712969},"source":{"system":"sec-edgar","filing":"0001628280-21-018953","document":"wf-form4_163226365231972.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000162828021018953/wf-form4_163226365231972.xml","form_type":"4"}},{"id":2562994,"issuer":{"id":4831,"kind":"organization","name":"PROCEPT BioRobotics Corp","symbol":"PRCT"},"owners":[{"id":91372,"kind":"organization","name":"CPMG Inc","position":1,"cik":"0001372218","reported_name":"CPMG Inc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":2,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":91373,"kind":"organization","name":"White Tailed Ptarmigan, LP","position":3,"cik":"0001882743","reported_name":"White Tailed Ptarmigan, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-21T18:34:24.000Z","date":"2021-09-17","kind":"purchase","acquired":true,"shares":440000,"price":25,"value":11000000.0,"ownership":{"direct":false,"nature":"By White Tailed Ptarmigan, LP"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents a purchase in the Issuer's public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"CPMG, Inc. is the general partner of White Tailed Ptarmigan, LP and has voting and investment control over the shares beneficially owned by White Tailed Ptarmigan, LP. Antal Desai, a member of our board of directors and a Partner of CPMG, Inc., along with Kent McGaughy, Jr., the sole shareholder and managing director of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by White Tailed Ptarmigan, LP. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by White Tailed Ptarmigan, LP except to the extent of any pecuniary interest therein. Antal Desai is separately reporting his deemed indirect ownership of the shares held by White Tailed Ptarmigan, LP."}],"balance_after":11222662,"source":{"system":"sec-edgar","filing":"0001628280-21-018953","document":"wf-form4_163226365231972.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000162828021018953/wf-form4_163226365231972.xml","form_type":"4"}},{"id":2562993,"issuer":{"id":4831,"kind":"organization","name":"PROCEPT BioRobotics Corp","symbol":"PRCT"},"owners":[{"id":91372,"kind":"organization","name":"CPMG Inc","position":1,"cik":"0001372218","reported_name":"CPMG Inc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":2,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":91373,"kind":"organization","name":"White Tailed Ptarmigan, LP","position":3,"cik":"0001882743","reported_name":"White Tailed Ptarmigan, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-21T18:34:24.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":10084910,"ownership":{"direct":false,"nature":"By White Tailed Ptarmigan, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"CPMG, Inc. is the general partner of White Tailed Ptarmigan, LP and has voting and investment control over the shares beneficially owned by White Tailed Ptarmigan, LP. Antal Desai, a member of our board of directors and a Partner of CPMG, Inc., along with Kent McGaughy, Jr., the sole shareholder and managing director of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by White Tailed Ptarmigan, LP. Each of Mr. Desai and Mr. McGaughy, Jr. disclaims beneficial ownership of the shares beneficially owned by White Tailed Ptarmigan, LP except to the extent of any pecuniary interest therein. Antal Desai is separately reporting his deemed indirect ownership of the shares held by White Tailed Ptarmigan, LP."}],"balance_after":10782662,"source":{"system":"sec-edgar","filing":"0001628280-21-018953","document":"wf-form4_163226365231972.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000162828021018953/wf-form4_163226365231972.xml","form_type":"4"}},{"id":2669974,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T17:25:08.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":690,"price":83.24,"value":57435.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $57,500."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in the following installments: 172 shares on September 10, 2021, 172 shares on December 10, 2021, 173 shares on March 10, 2022, and 173 shares on June 10, 2022, respectively, subject to continued service through each vesting date."}],"balance_after":690,"derivative":{"exercise_price":146.01,"expiration_date":"2031-06-10","underlying":"Class A common stock","underlying_shares":690},"source":{"system":"sec-edgar","filing":"0001567619-21-012075","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000156761921012075/doc1.xml","form_type":"4"}},{"id":2669973,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T17:25:08.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 4 equal installments on September 10, 2021, December 10, 2021, March 10, 2022, and June 10, 2022, subject to continued service through each vesting date."}],"balance_after":5000,"derivative":{"exercise_price":146.01,"expiration_date":"2031-06-10","underlying":"Class A common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001567619-21-012075","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000156761921012075/doc1.xml","form_type":"4"}},{"id":2771812,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-03-25T17:28:43.000Z","date":"2021-03-23","kind":"exercise","acquired":false,"shares":795152,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Ibisibill, LP (the \"LP\"). CPMG, Inc. is the general partner of the LP and has voting and investment control over the\nshares beneficially owned by the LP. The Reporting Person is the sole shareholder and managing director of CPMG, Inc. and may be deemed to\nshare voting and investment power with respect to the shares beneficially owned by the LP. The Reporting Person disclaims beneficial\nownership of the shares beneficially owned by LP except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":954182},"source":{"system":"sec-edgar","filing":"0001209191-21-023063","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000120919121023063/doc4.xml","form_type":"4"}},{"id":2771811,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-03-25T17:28:43.000Z","date":"2021-03-23","kind":"exercise","acquired":false,"shares":5895507,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Ibisibill, LP (the \"LP\"). CPMG, Inc. is the general partner of the LP and has voting and investment control over the\nshares beneficially owned by the LP. The Reporting Person is the sole shareholder and managing director of CPMG, Inc. and may be deemed to\nshare voting and investment power with respect to the shares beneficially owned by the LP. The Reporting Person disclaims beneficial\nownership of the shares beneficially owned by LP except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7074608},"source":{"system":"sec-edgar","filing":"0001209191-21-023063","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000120919121023063/doc4.xml","form_type":"4"}},{"id":2771810,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-25T17:28:43.000Z","date":"2021-03-23","kind":"purchase","acquired":true,"shares":450000,"price":20,"value":9000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Ibisibill, LP (the \"LP\"). CPMG, Inc. is the general partner of the LP and has voting and investment control over the\nshares beneficially owned by the LP. The Reporting Person is the sole shareholder and managing director of CPMG, Inc. and may be deemed to\nshare voting and investment power with respect to the shares beneficially owned by the LP. The Reporting Person disclaims beneficial\nownership of the shares beneficially owned by LP except to the extent of any pecuniary interest therein."}],"balance_after":8478790,"source":{"system":"sec-edgar","filing":"0001209191-21-023063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000120919121023063/doc4.xml","form_type":"4"}},{"id":2771809,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-25T17:28:43.000Z","date":"2021-03-23","kind":"exercise","acquired":true,"shares":954182,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Ibisibill, LP (the \"LP\"). CPMG, Inc. is the general partner of the LP and has voting and investment control over the\nshares beneficially owned by the LP. The Reporting Person is the sole shareholder and managing director of CPMG, Inc. and may be deemed to\nshare voting and investment power with respect to the shares beneficially owned by the LP. The Reporting Person disclaims beneficial\nownership of the shares beneficially owned by LP except to the extent of any pecuniary interest therein."}],"balance_after":8028790,"source":{"system":"sec-edgar","filing":"0001209191-21-023063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000120919121023063/doc4.xml","form_type":"4"}},{"id":2771808,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-25T17:28:43.000Z","date":"2021-03-23","kind":"exercise","acquired":true,"shares":7074608,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Ibisibill, LP (the \"LP\"). CPMG, Inc. is the general partner of the LP and has voting and investment control over the\nshares beneficially owned by the LP. The Reporting Person is the sole shareholder and managing director of CPMG, Inc. and may be deemed to\nshare voting and investment power with respect to the shares beneficially owned by the LP. The Reporting Person disclaims beneficial\nownership of the shares beneficially owned by LP except to the extent of any pecuniary interest therein."}],"balance_after":7074608,"source":{"system":"sec-edgar","filing":"0001209191-21-023063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000120919121023063/doc4.xml","form_type":"4"}},{"id":2776165,"issuer":{"id":7177,"kind":"organization","name":"Instil Bio, Inc."},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-22T20:55:30.000Z","date":"2021-03-18","kind":"grant","acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in 36 equal monthly installments commencing on April 18, 2021, subject to the Report Person's continued service as a director through the vesting date."}],"balance_after":52000,"derivative":{"exercise_price":20,"expiration_date":"2031-03-18","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001209191-21-022476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000120919121022476/doc4.xml","form_type":"4"}},{"id":2930061,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2020-12-29T17:42:48.000Z","date":"2020-12-23","kind":"other","acquired":false,"shares":166666,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The transaction represents the distribution of shares by Flamingo Fund, LP to its sole limited partner. No sale of shares was made by CPMG, Inc. or Flamingo Fund, LP in connection with the transaction. The transaction reflects 1.3% (63,481 shares) of the 4,756,424 Class A and Class B shares of the issuer beneficially owned by CPMG, Inc. prior to the date of the transaction."},{"field":"kind","element":"transactionCoding","label":"F6","text":"The transaction represents the revocation of CPMG, Inc.'s investment discretion with respect to the shares held by the Blackwell Account. No distribution or sale of shares was made by CPMG, Inc. in connection with the transaction. The transaction reflects 2.2% (103,185 shares) of the 4,756,424 Class A and Class B shares of the issuer beneficially owned by CPMG, Inc. prior to the date of the transaction."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction represents the distribution of shares by Flamingo Fund, LP to its sole limited partner. No sale of shares was made by CPMG, Inc. or Flamingo Fund, LP in connection with the transaction. The transaction reflects 1.3% (63,481 shares) of the 4,756,424 Class A and Class B shares of the issuer beneficially owned by CPMG, Inc. prior to the date of the transaction."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction represents the revocation of CPMG, Inc.'s investment discretion with respect to the shares held by the Blackwell Account. No distribution or sale of shares was made by CPMG, Inc. in connection with the transaction. The transaction reflects 2.2% (103,185 shares) of the 4,756,424 Class A and Class B shares of the issuer beneficially owned by CPMG, Inc. prior to the date of the transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a sole director and sole shareholder of CPMG, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2896901,"source":{"system":"sec-edgar","filing":"0001140361-20-029806","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036120029806/form4.xml","form_type":"4"}},{"id":3078683,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2020-07-21T18:40:52.000Z","date":"2020-07-17","kind":"purchase","acquired":true,"shares":1200000,"price":1.25,"value":1500000.0,"ownership":{"direct":false,"nature":"By Roadrunner Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were acquired directly from the Issuer pursuant to a securities purchase agreement dated as of July 17, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were acquired directly from the Issuer pursuant to a securities purchase agreement dated as of July 17, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. and the Managing Director of CPMG, Inc. have shared voting and investment control over the securities owned by each of Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\"). The Reporting Person is the Managing Director of CPMG, Inc. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. and the Managing Director of CPMG, Inc. have shared voting and investment control over the securities owned by each of Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\"). The Reporting Person is the Managing Director of CPMG, Inc. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1707208,"source":{"system":"sec-edgar","filing":"0000905148-20-000826","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514820000826/form4.xml","form_type":"4"}},{"id":3078682,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2020-07-21T18:40:52.000Z","date":"2020-07-17","kind":"purchase","acquired":true,"shares":400000,"price":1.25,"value":500000.0,"ownership":{"direct":false,"nature":"By Killdeer Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were acquired directly from the Issuer pursuant to a securities purchase agreement dated as of July 17, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were acquired directly from the Issuer pursuant to a securities purchase agreement dated as of July 17, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. and the Managing Director of CPMG, Inc. have shared voting and investment control over the securities owned by each of Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\"). The Reporting Person is the Managing Director of CPMG, Inc. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. and the Managing Director of CPMG, Inc. have shared voting and investment control over the securities owned by each of Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\"). The Reporting Person is the Managing Director of CPMG, Inc. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":415244,"source":{"system":"sec-edgar","filing":"0000905148-20-000826","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514820000826/form4.xml","form_type":"4"}},{"id":3078681,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2020-07-21T18:40:52.000Z","date":"2020-07-17","kind":"purchase","acquired":true,"shares":180000,"price":1.25,"value":225000.0,"ownership":{"direct":false,"nature":"By Curlew Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were acquired directly from the Issuer pursuant to a securities purchase agreement dated as of July 17, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were acquired directly from the Issuer pursuant to a securities purchase agreement dated as of July 17, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. and the Managing Director of CPMG, Inc. have shared voting and investment control over the securities owned by each of Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\"). The Reporting Person is the Managing Director of CPMG, Inc. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. and the Managing Director of CPMG, Inc. have shared voting and investment control over the securities owned by each of Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\"). The Reporting Person is the Managing Director of CPMG, Inc. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":477120,"source":{"system":"sec-edgar","filing":"0000905148-20-000826","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514820000826/form4.xml","form_type":"4"}},{"id":3103009,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2020-06-22T20:25:50.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":699,"price":82.15,"value":57422.85,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $57,500.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in the following installments: 174 shares on September 10, 2020, and 175 shares on December 10, 2020, March 10, 2021, and June 10, 2021, respectively, subject to continued service through each vesting date."}],"balance_after":699,"derivative":{"exercise_price":130.92,"expiration_date":"2030-06-10","underlying":"Class A common stock","underlying_shares":699},"source":{"system":"sec-edgar","filing":"0000905148-20-000715","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514820000715/form4.xml","form_type":"4"}},{"id":3103008,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2020-06-22T20:25:50.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":6300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 4 equal installments on September 10, 2020, December 10, 2020, March 10, 2021, and June 10, 2021, subject to continued service through each vesting date."}],"balance_after":6300,"derivative":{"exercise_price":130.92,"expiration_date":"2030-06-10","underlying":"Class A common stock","underlying_shares":6300},"source":{"system":"sec-edgar","filing":"0000905148-20-000715","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514820000715/form4.xml","form_type":"4"}},{"id":3318094,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2020-01-06T18:33:23.000Z","date":"2020-01-02","kind":"other","acquired":true,"shares":38108,"ownership":{"direct":false,"nature":"By Roadrunner Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Issuer's 6.0% Convertible Debentures due 2024 (\"Notes\"), the semi-annual interest payment due on the Notes was paid by the Issuer in shares of the Issuer's common stock, based on the interest rate of 6.00% per year and the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the interest payment date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Issuer's 6.0% Convertible Debentures due 2024 (\"Notes\"), the semi-annual interest payment due on the Notes was paid by the Issuer in shares of the Issuer's common stock, based on the interest rate of 6.00% per year and the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the interest payment date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. and the Managing Directors of CPMG, Inc. have shared voting and investment control over the securities owned by each Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\"). The Reporting Person is a Managing Director of CPMG, Inc. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. and the Managing Directors of CPMG, Inc. have shared voting and investment control over the securities owned by each Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\"). The Reporting Person is a Managing Director of CPMG, Inc. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":507208,"source":{"system":"sec-edgar","filing":"0001140361-20-000331","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036120000331/form4.xml","form_type":"4"}},{"id":3318093,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2020-01-06T18:33:23.000Z","date":"2020-01-02","kind":"other","acquired":true,"shares":15244,"ownership":{"direct":false,"nature":"By Killdeer Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Issuer's 6.0% Convertible Debentures due 2024 (\"Notes\"), the semi-annual interest payment due on the Notes was paid by the Issuer in shares of the Issuer's common stock, based on the interest rate of 6.00% per year and the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the interest payment date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Issuer's 6.0% Convertible Debentures due 2024 (\"Notes\"), the semi-annual interest payment due on the Notes was paid by the Issuer in shares of the Issuer's common stock, based on the interest rate of 6.00% per year and the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the interest payment date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. and the Managing Directors of CPMG, Inc. have shared voting and investment control over the securities owned by each Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\"). The Reporting Person is a Managing Director of CPMG, Inc. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. and the Managing Directors of CPMG, Inc. have shared voting and investment control over the securities owned by each Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\"). The Reporting Person is a Managing Director of CPMG, Inc. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":15244,"source":{"system":"sec-edgar","filing":"0001140361-20-000331","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036120000331/form4.xml","form_type":"4"}},{"id":3318092,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2020-01-06T18:33:23.000Z","date":"2020-01-02","kind":"other","acquired":true,"shares":3811,"ownership":{"direct":false,"nature":"By Curlew Fund, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Issuer's 6.0% Convertible Debentures due 2024 (\"Notes\"), the semi-annual interest payment due on the Notes was paid by the Issuer in shares of the Issuer's common stock, based on the interest rate of 6.00% per year and the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the interest payment date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Issuer's 6.0% Convertible Debentures due 2024 (\"Notes\"), the semi-annual interest payment due on the Notes was paid by the Issuer in shares of the Issuer's common stock, based on the interest rate of 6.00% per year and the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the interest payment date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CPMG, Inc. and the Managing Directors of CPMG, Inc. have shared voting and investment control over the securities owned by each Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\"). The Reporting Person is a Managing Director of CPMG, Inc. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"CPMG, Inc. and the Managing Directors of CPMG, Inc. have shared voting and investment control over the securities owned by each Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\"). The Reporting Person is a Managing Director of CPMG, Inc. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":297120,"source":{"system":"sec-edgar","filing":"0001140361-20-000331","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036120000331/form4.xml","form_type":"4"}},{"id":3340782,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class B Common Stock","published_at":"2019-12-16T16:16:00.000Z","date":"2019-12-12","kind":"exercise","acquired":false,"shares":30478,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"These shares of Class B common stock are convertible into Class A common stock on a one-for-one basis at the holder's election at any time for no additional consideration, and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares of Class B common stock are convertible into Class A common stock on a one-for-one basis at the holder's election at any time for no additional consideration, and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These shares of Class B common stock are convertible into Class A common stock on a one-for-one basis at the holder's election at any time for no additional consideration, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These shares of Class B common stock are convertible into Class A common stock on a one-for-one basis at the holder's election at any time for no additional consideration, and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of Class A common stock and Class B common stock are held in escrow for a charitable donee by American Stock Transfer & Trust Company, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":30478},"source":{"system":"sec-edgar","filing":"0000905148-19-001034","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514819001034/form4.xml","form_type":"4"}},{"id":3340781,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2019-12-16T16:16:00.000Z","date":"2019-12-12","kind":"exercise","acquired":true,"shares":30478,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares of Class B common stock are convertible into Class A common stock on a one-for-one basis at the holder's election at any time for no additional consideration, and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of Class A common stock and Class B common stock are held in escrow for a charitable donee by American Stock Transfer & Trust Company, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":33217,"source":{"system":"sec-edgar","filing":"0000905148-19-001034","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514819001034/form4.xml","form_type":"4"}},{"id":3368043,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2019-11-18T17:21:48.000Z","date":"2019-11-18","kind":"purchase","acquired":true,"shares":40218,"price":183,"value":7359894.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a co-director and co-shareholder of CPMG, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3063567,"source":{"system":"sec-edgar","filing":"0000905148-19-001002","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514819001002/form4.xml","form_type":"4"}},{"id":3438627,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.0% Convertible Debentures due 2024","published_at":"2019-08-14T20:36:43.000Z","date":"2019-08-12","kind":"purchase","acquired":true,"price":4625000,"reported_value":4625000,"ownership":{"direct":false,"nature":"By Roadrunner Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to a securities purchase agreement (the \"Purchase Agreement\"), dated as of August 7, 2019, the Issuer issued and sold $20.0 million aggregate principal amount of 6.0% Convertible Debentures (the \"Notes\") to certain purchasers.  The Notes are initially convertible into shares of the Issuer's common stock, par value $0.001 per share, subject to certain adjustments."},{"field":"reported_value","element":"transactionTotalValue","label":"F2","text":"Interest on the Notes is payable semi-annually in shares of the Issuer's common stock on January 1 and July 1 of each year, beginning on January 1, 2020, at a rate of 6.00% per year and based on the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the applicable interest payment date. However, interest will be paid in-kind on such interest payments dates if (i) the average VWAP of the Issuer's common stock for the 10 consecutive trading days immediately preceding such interest payment date is less than $2.50 per share, or (ii) the Issuer fails to satisfy certain common stock delivery obligations upon conversion of the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"CPMG, Inc. and the Managing Directors of CPMG, Inc. have shared voting and investment control over the securities owned by each Curlew Fund, LP, Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\").  The Reporting Person is a Managing Director of each Fund.  The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"derivative":{"exercise_price":3.25,"exercise_date":"2019-08-12","expiration_date":"2024-08-12","underlying":"Common Sock","underlying_shares":1423077},"source":{"system":"sec-edgar","filing":"0001251769-19-000072","document":"wf-form4_156582938729360.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000125176919000072/wf-form4_156582938729360.xml","form_type":"4"}},{"id":3438626,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.0% Convertible Debentures due 2024","published_at":"2019-08-14T20:36:43.000Z","date":"2019-08-12","kind":"purchase","acquired":true,"price":1850000,"reported_value":1850000,"ownership":{"direct":false,"nature":"By Killdeer Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to a securities purchase agreement (the \"Purchase Agreement\"), dated as of August 7, 2019, the Issuer issued and sold $20.0 million aggregate principal amount of 6.0% Convertible Debentures (the \"Notes\") to certain purchasers.  The Notes are initially convertible into shares of the Issuer's common stock, par value $0.001 per share, subject to certain adjustments."},{"field":"reported_value","element":"transactionTotalValue","label":"F2","text":"Interest on the Notes is payable semi-annually in shares of the Issuer's common stock on January 1 and July 1 of each year, beginning on January 1, 2020, at a rate of 6.00% per year and based on the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the applicable interest payment date. However, interest will be paid in-kind on such interest payments dates if (i) the average VWAP of the Issuer's common stock for the 10 consecutive trading days immediately preceding such interest payment date is less than $2.50 per share, or (ii) the Issuer fails to satisfy certain common stock delivery obligations upon conversion of the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"CPMG, Inc. and the Managing Directors of CPMG, Inc. have shared voting and investment control over the securities owned by each Curlew Fund, LP, Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\").  The Reporting Person is a Managing Director of each Fund.  The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"derivative":{"exercise_price":3.25,"exercise_date":"2019-08-12","expiration_date":"2024-08-12","underlying":"Common Sock","underlying_shares":569231},"source":{"system":"sec-edgar","filing":"0001251769-19-000072","document":"wf-form4_156582938729360.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000125176919000072/wf-form4_156582938729360.xml","form_type":"4"}},{"id":3438625,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"6.0% Convertible Debentures due 2024","published_at":"2019-08-14T20:36:43.000Z","date":"2019-08-12","kind":"purchase","acquired":true,"price":462500,"reported_value":462500,"ownership":{"direct":false,"nature":"By Curlew Fund, LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to a securities purchase agreement (the \"Purchase Agreement\"), dated as of August 7, 2019, the Issuer issued and sold $20.0 million aggregate principal amount of 6.0% Convertible Debentures (the \"Notes\") to certain purchasers.  The Notes are initially convertible into shares of the Issuer's common stock, par value $0.001 per share, subject to certain adjustments."},{"field":"reported_value","element":"transactionTotalValue","label":"F2","text":"Interest on the Notes is payable semi-annually in shares of the Issuer's common stock on January 1 and July 1 of each year, beginning on January 1, 2020, at a rate of 6.00% per year and based on the average volume-weighted average price, or VWAP, of the Issuer's common stock for the 10 consecutive trading days immediately preceding the applicable interest payment date. However, interest will be paid in-kind on such interest payments dates if (i) the average VWAP of the Issuer's common stock for the 10 consecutive trading days immediately preceding such interest payment date is less than $2.50 per share, or (ii) the Issuer fails to satisfy certain common stock delivery obligations upon conversion of the Notes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"CPMG, Inc. and the Managing Directors of CPMG, Inc. have shared voting and investment control over the securities owned by each Curlew Fund, LP, Killdeer Fund, LP, and Roadrunner Fund, LP (each, a \"Fund\").  The Reporting Person is a Managing Director of each Fund.  The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"derivative":{"exercise_price":3.25,"exercise_date":"2019-08-12","expiration_date":"2024-08-12","underlying":"Common Sock","underlying_shares":142308},"source":{"system":"sec-edgar","filing":"0001251769-19-000072","document":"wf-form4_156582938729360.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000125176919000072/wf-form4_156582938729360.xml","form_type":"4"}},{"id":3489425,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T15:02:18.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":892,"price":57.59,"value":51370.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $51,370.28."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 4 equal installments on September 12, 2019, December 12, 2019, March 12, 2020, and June 12, 2020, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":892,"derivative":{"exercise_price":88.75,"expiration_date":"2029-06-12","underlying":"Class B common stock","underlying_shares":892},"source":{"system":"sec-edgar","filing":"0000905148-19-000643","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514819000643/form4.xml","form_type":"4"}},{"id":3489424,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T15:02:18.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 4 equal installments on September 12, 2019, December 12, 2019, March 12, 2020, and June 12, 2020, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":9000,"derivative":{"exercise_price":88.75,"expiration_date":"2029-06-12","underlying":"Class B common stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000905148-19-000643","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514819000643/form4.xml","form_type":"4"}},{"id":3733918,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2018-12-12T17:58:37.000Z","date":"2018-12-12","kind":"purchase","acquired":true,"shares":1418,"price":59.8952,"value":84931.3936,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This price reflects the weighted average purchase price for open-market purchases on December 12, 2018, within a $1.00 range.  The actual prices for these transactions range from $59.84 to $59.98, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a co-director and co-shareholder of CPMG, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3023349,"source":{"system":"sec-edgar","filing":"0000905148-18-000921","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514818000921/form4.xml","form_type":"4"}},{"id":3733917,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2018-12-12T17:58:37.000Z","date":"2018-12-11","kind":"purchase","acquired":true,"shares":52809,"price":60.0719,"value":3172336.9671,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This price reflects the weighted average purchase price for open-market purchases on December 11, 2018, within a $1.00 range.  The actual prices for these transactions range from $59.52 to $60.145, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a co-director and co-shareholder of CPMG, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3021931,"source":{"system":"sec-edgar","filing":"0000905148-18-000921","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514818000921/form4.xml","form_type":"4"}},{"id":3733916,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2018-12-12T17:58:37.000Z","date":"2018-12-10","kind":"purchase","acquired":true,"shares":29347,"price":59.5303,"value":1747035.7141,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This price reflects the weighted average purchase price for open-market purchases on December 10, 2018, within a $1.00 range.  The actual prices for these transactions range from $59.24 to $59.80, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a co-director and co-shareholder of CPMG, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2969122,"source":{"system":"sec-edgar","filing":"0000905148-18-000921","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514818000921/form4.xml","form_type":"4"}},{"id":3733915,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2018-12-12T17:58:37.000Z","date":"2018-12-10","kind":"purchase","acquired":true,"shares":1078,"price":58.6218,"value":63194.3004,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This price reflects the weighted average purchase price for open-market purchases on December 10, 2018, within a $1.00 range.  The actual prices for these transactions range from $58.235 to $59.17, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a co-director and co-shareholder of CPMG, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2939775,"source":{"system":"sec-edgar","filing":"0000905148-18-000921","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514818000921/form4.xml","form_type":"4"}},{"id":3733914,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2018-12-12T17:58:37.000Z","date":"2018-12-10","kind":"purchase","acquired":true,"shares":26174,"price":57.9329,"value":1516335.7246,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This price reflects the weighted average purchase price for open-market purchases on December 10, 2018, within a $1.00 range.  The actual prices for these transactions range from $57.235 to $58.23, inclusive.  The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnotes (6) through (10) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a co-director and co-shareholder of CPMG, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2938697,"source":{"system":"sec-edgar","filing":"0000905148-18-000921","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514818000921/form4.xml","form_type":"4"}},{"id":3892350,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2018-06-15T08:05:29.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":1844,"price":26.4918,"value":48850.8792,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $48,875."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 4 equal installments on September 13, 2018, December 13, 2018, March 13, 2019, and June 13, 2019, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":1844,"derivative":{"exercise_price":39.48,"expiration_date":"2028-06-13","underlying":"Class B common stock","underlying_shares":1844},"source":{"system":"sec-edgar","filing":"0000905148-18-000555","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514818000555/form4.xml","form_type":"4"}},{"id":3892349,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2018-06-15T08:05:29.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 4 equal installments on September 13, 2018, December 13, 2018, March 13, 2019, and June 13, 2019, subject to continued service through each vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date."}],"balance_after":8000,"derivative":{"exercise_price":39.48,"expiration_date":"2028-06-13","underlying":"Class B common stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0000905148-18-000555","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000090514818000555/form4.xml","form_type":"4"}},{"id":4118915,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2017-12-29T17:07:50.000Z","date":"2017-12-29","kind":"purchase","acquired":true,"shares":17000,"price":28.4715,"value":484015.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This price reflects the weighted average purchase price for open-market purchases on December 29, 2017, within a $1.00 range.  The actual prices for these transactions range from $28.40 to $28.50 inclusive.  The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a co-director and co-shareholder of CPMG, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2912523,"source":{"system":"sec-edgar","filing":"0001140361-17-047823","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036117047823/form4.xml","form_type":"4"}},{"id":4120102,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":38682,"kind":"person","name":"McGaughy R Kent Jr","position":1,"cik":"0001402856","reported_name":"McGaughy R Kent Jr","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Class A common stock","published_at":"2017-12-28T19:01:51.000Z","date":"2017-12-28","kind":"purchase","acquired":true,"shares":200,"price":26.1,"value":5220.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a co-director and co-shareholder of CPMG, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2895523,"source":{"system":"sec-edgar","filing":"0001140361-17-047649","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1402856/000114036117047649/form4.xml","form_type":"4"}}],"next_cursor":"2017-12-28T19:01:51.000000Z,4120102"}